



**BioLight Life Sciences Ltd.**

**(the "Company")**

July 3, 2024

**To: Israel Security Authority  
[www.isa.gov.il](http://www.isa.gov.il)**

**TASE Tel Aviv Stock Exchange  
[www.tase.co.il](http://www.tase.co.il)**

Re: **Completion of Sale of all of Company's shares (Exit) in Belkin Vision (portfolio company)**

BioLight [TASE:BOLT] is pleased to announce that on July 2, 2024 ("Completion Date"), the merger transaction of Belkin Vision Ltd. ("Belkin") with Alcon Pharmaceuticals Ltd. ("Alcon") was completed, whereby all of Belkin's shares, including all shares held by the Company (approximately 4% of its issued and paid-up capital), were transferred to Alcon's ownership, and Belkin became a wholly-owned subsidiary of Alcon ("Merger Agreement" and "Merger Transaction," respectively).

Belkin's shareholders are entitled to a total consideration of approximately \$466 million, consisting of: 1. Consideration contingent upon meeting the milestones set forth in the Merger Agreement concerning annual sales revenue targets of Belkin's products by Alcon, which may reach a cumulative amount of up to approximately \$385 million; and 2. A total cash consideration of approximately \$81 million at the Completion Date.

Accordingly, on the Completion Date, the Company's share of the immediate consideration received by the Merger Transaction trustee (paying agent) amounted to approximately 8.9 million ILS in cash. Additionally, the Company is entitled to future consideration of up to approximately \$10.8 million, to be paid in periodic installments, contingent upon meeting the milestones set forth in the Merger Agreement.

As stated by Alcon, the completion of the Merger Transaction expands its existing glaucoma treatment portfolio, with the possibility of a first-line laser treatment. Alcon intends to accelerate the global adoption of DSLT technology as a first-line treatment using the laser device developed by Belkin for glaucoma treatment.

***Forward-looking statement*** - the information, details and Company's estimates contained in this report including the possibility of meeting milestones for annual sales of the Belkin Vision product (if any), and the payments to which the Company may be entitled in the future in accordance with the meeting of such milestones, are "forward-looking information" as defined in the Securities Law, 1968-5778 which involves high uncertainty, and is based, among other things, on third parties and on many variables over which the Company and Belkin Vision do not necessarily have control, and therefore it is possible that the information, details and estimates as stated, in practice, will not be realized and/or they will not be realized in full and/or they will be realized in a way that is fundamentally different from what was estimated or expected in the first place.

### **About Belkin**

Belkin Vision is engaged in the development and commercialization of a laser device, the Eagle™, whose purpose is to allow accessible first-line glaucoma care. As informed to the Company, In May 2022, Belkin Vision received a CE for her product under the new European directive ("MDR") and in December 2023, Belkin Vision received an FDA approval for her product.

### **About Alcon<sup>1</sup>**

The Alcon group (which includes the buyer in the Merger Transaction) is the largest eye care device company in the world, with complementary businesses in surgical and vision care. The Alcon group's products serve patients in more than 140 countries in the world and its main offices are in the USA.

### **About BioLight**

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.

---

### **Free translation: non-binding**

*This is a translated version of the Company's immediate report in Hebrew as filed with the Israeli SEC - created for convenience purposes only. In case of contradiction, the Hebrew version will prevail.*

---

<sup>1</sup> [About Us | Alcon.com](https://www.alcon.com)